Results 231 to 240 of about 106,568 (297)

Poly(ADP-ribose) polymerase-1 (PARP-1) gene polymorphisms in schizophrenia: A case-control study in the Turkish population. [PDF]

Medicine (Baltimore)
Şenormanci Ö, Turan Ç, Metin S, Karakaş Çelik S, Yilmaz B, Şenormanci G, Ünal S.   +6 more
europepmc   +1 more source

In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma

ChemMedChem, Volume 21, Issue 8, 28 April 2026.
Inhibition of DNA damage repair is a common mechanism to induce cancer cell death and, therefore, to treat cancers such as breast, prostate and ovarian cancer. This approach, although very attractive, has not been feasible for treating brain tumours due to the stringent structural features necessary for pharmaceutical agents to cross the blood–brain ...
Carina Dumo, Faheem, Peter J. Choi, Nicholas J. Pederson, Yuge Liu, Mike Dragunow, Thomas I‐H. Park, Katharine L. Diehl, Jiney Jose   +8 more
wiley   +1 more source

Retrospective Analysis of <i>BRCA</i>-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors. [PDF]

JCO Precis Oncol
Rao M, Merrill M, Troxel M, Chiang S, Momeni-Boroujeni A, Hensley ML, Schram AM.   +6 more
europepmc   +1 more source

Efficacy and safety of poly ADP-ribose polymerase inhibitors (PARPis) in extensive-stage small-cell lung cancer (ES-SCLC) treatment: a systematic review and meta-analysis. [PDF]

J Thorac Dis
Cheng CC, Ma LJ, Pang XM, Huang TS, Wang MF, Xu JY, Wang RQ, Chen X, Sun K, Zhao WX, Yan M, Wang P.   +11 more
europepmc   +1 more source

Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors. [PDF]

JCO Precis Oncol
O'Sullivan Coyne G, Do KT, Kummar S, Piha-Paul S, Rubinstein L, Kinders R, Parchment RE, Wilsker D, Ferry-Galow K, Miller B, Takebe N, Juwara L, Ong MJ, Bruns A, Hogu M, Naqash AR, Mittra A, Voth AR, Doroshow JH, Chen AP.   +19 more
europepmc   +1 more source

Dual targeting of Aurora Kinase A and poly (ADP-ribose) polymerase as a therapeutic option for patients with ovarian cancer: preclinical evaluations. [PDF]

J Cancer Res Clin Oncol
Turaga SM, Hembruff SL, Savelieff MG, Ghosh A, Puri RV, Pathak HB, Paradiso LJ, Myers TJ, Li A, Godwin AK.   +9 more
europepmc   +1 more source

Beyond Glucose: A Brain Energy Bottleneck Hypothesis for Multi‐Energy Substrates in Hypoglycaemia Rescue

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3474-3479, May 2026.
D. Russell‐Jones, M. Laffan, J. Mader
wiley   +1 more source

Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. [PDF]

JCO Precis Oncol
Yadav S, Couch FJ, Hillman S, Luo L, Li W, Li Q, Hayes JF, Earla JR, Xu X.   +8 more
europepmc   +1 more source

Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review). [PDF]

Oncol Lett
Han Y, Wei L.
europepmc   +1 more source

Clinical evaluation of combined programmed cell death protein 1 inhibitor and poly(ADP-ribose) polymerase inhibitor in metastatic castration-resistant prostate cancer patients: Insights from a real-world study. [PDF]

Curr Urol
Shao Y, Liu Z, Zhang Y, Liu Y, Huang H, Fu Z, Yang Z, Wang Z, Zhang S, Wang Y.   +9 more
europepmc   +1 more source